Selective suppression of T-cell activation by administration of MHC class II-binding peptides.
Adorini
L
L
Preclinical Research, Sandoz Pharma, Ltd, Basel, Switzerland.
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D002352:Carrier Proteins / Q000008:administration & dosage*; D000949:Histocompatibility Antigens Class II / Q000378:metabolism*; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology*
D002352:Carrier Proteins; D000949:Histocompatibility Antigens Class II